Roughly 14 peptides moved from a restricted regulatory category to a legally compoundable one in early 2026 — a shift that reversed years of restricted access for researchers, clinicians, and patients alike. The 2026 Compounded Peptide Policy Shift: What Returning Category-1 Peptides Mean for Research Access is not just a regulatory footnote. It fundamentally changes how compounds like CJC-1295, ipamorelin, selank, and epithalon can be obtained, studied, and prescribed under physician supervision.

Key Takeaways

• In February 2026, HHS reclassified approximately 14 peptides from Category 2 to Category 1, restoring legal compounding access.
• The FDA formally moved 12 peptides to Category 1 in April 2026, including CJC-1295, ipamorelin, selank, and epithalon.
• Category 1 status allows licensed 503A and 503B compounding pharmacies to prepare these peptides with a valid prescription.
• BPC-157 and TB-500 remain on Category 2 pending an FDA advisory committee review scheduled for July 23-24, 2026.
• Reclassification does not equal FDA drug approval — these remain off-label compounds requiring physician oversight.

---

Understanding the Category System Behind the 2026 Compounded Peptide Policy Shift

The FDA's peptide compounding framework sorts compounds into two main categories. Category 1 peptides can be legally compounded by licensed pharmacies under the 503A (patient-specific) and 503B (outsourcing facility) frameworks when a valid physician prescription exists. Category 2 peptides are restricted from compounding entirely, regardless of prescription status.

Before 2026, many research-relevant peptides had been moved to Category 2, effectively cutting off access through regulated pharmacy channels. That changed in February 2026 when HHS Secretary Robert F. Kennedy Jr. announced the reclassification of approximately 14 peptides back to Category 1. The FDA followed with a formal reclassification of 12 peptides in April 2026.

Peptides returned to Category 1 include:

Peptide	Primary Research Area
CJC-1295	Growth hormone secretion
Ipamorelin	GH secretagogue research
Selank	Neuropeptide and anxiolytic research
Semax	Cognitive and neuroprotective research
Epithalon	Longevity and telomere research
DSIP	Sleep and stress regulation
Thymulin	Immune modulation

For researchers exploring CJC-1295 and ipamorelin research themes, this reclassification reopens a pathway that had been effectively closed since the original Category 2 restrictions took hold.

---

What the 2026 Compounded Peptide Policy Shift Means for Research Access in Practice

Reclassification is not the same as FDA drug approval. This distinction matters. Category 1 status means a licensed compounding pharmacy can legally prepare these peptides for a specific patient under physician supervision. It does not mean these compounds have passed the full FDA drug approval process. They remain off-label therapeutics.

"Category 1 status restores a legal, quality-controlled supply chain — it does not confer the same standing as an FDA-approved finished drug product."

For supervised research and clinical use, this is still a significant development. Licensed 503A pharmacies can now compound selank and epithalon for patients with valid prescriptions, applying pharmaceutical-grade quality controls and testing standards in the process.

Researchers working across longevity peptide research and metabolic pathways will find the restored access to growth hormone secretagogues particularly relevant. Compounds like tesa, which already held FDA approval for a specific indication, now sit alongside newly reclassified peptides in a more coherent regulatory landscape.

What researchers and providers should verify before sourcing:

• Confirm the pharmacy holds a valid 503A or 503B license
• Obtain a physician prescription before any compounding order
• Check state-level regulations, which may impose additional restrictions
• Review the FDA's current peptide status tracker for any updates post-April 2026

---

Peptides Still on Category 2 and What Comes Next

Not every restricted peptide received reclassification. As of mid-2026, BPC-157 and TB-500 remain on Category 2 and cannot be legally compounded through licensed pharmacies. The FDA Peptide Compounding Advisory Committee (PCAC) is scheduled to review these compounds at its meeting on July 23-24, 2026. The outcome of that meeting could further reshape access for researchers focused on tissue repair and recovery pathways.

Separately, semaglutide and tirzepatide remain on Category 2 and are still banned from compounding, reflecting ongoing enforcement around GLP-1 receptor agonists.

Researchers tracking BPC-157 research themes should monitor the PCAC meeting outcome closely. Similarly, those following TB-500 research will want to watch for any post-meeting guidance from the FDA.

For a broader view of what is new in peptide research in 2026, the regulatory environment is as important as the science itself. Providers must stay current on federal rules, the 503A/503B framework, and state-specific restrictions to maintain compliant practices.

---

Conclusion

The 2026 Compounded Peptide Policy Shift: What Returning Category-1 Peptides Mean for Research Access represents a meaningful reset for the peptide research community. Twelve to fourteen compounds have moved back into a legally compoundable status, restoring quality-controlled access for physicians and researchers who rely on these tools.

Actionable next steps for researchers and providers:

1. Verify current Category 1 status for any peptide of interest using the FDA's official tracker before sourcing.
2. Work only with licensed 503A or 503B pharmacies to ensure pharmaceutical-grade quality and legal compliance.
3. Obtain a valid physician prescription — this is a non-negotiable requirement under the reclassification framework.
4. Monitor the July 23-24, 2026 PCAC meeting for updates on BPC-157, TB-500, and any additional reclassifications.
5. Review state regulations alongside federal rules, as state-level restrictions can still limit access even when federal status is Category 1.

The regulatory landscape is actively evolving. Staying informed is not optional — it is the foundation of responsible, compliant peptide research in 2026.